Sight Sciences (NASDAQ:SGHT) Releases Earnings Results, Meets Expectations

Posted by George Bondi on Nov 4th, 2026

Sight Sciences (NASDAQ:SGHT – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12), FiscalAI reports. Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%. The business had revenue of $24.92 million during the quarter, compared to the consensus estimate of $23.55 million.

Here are the key takeaways from Sight Sciences’ conference call:

Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% year over year, and raised 2026 revenue guidance to $92 million–$93 million, implying about 20% growth. Adjusted operating expense guidance was maintained at $92 million–$94 million.
IDE revenue reached a record $3.9 million, up 45% sequentially, prompting the company to raise its full-year IDE outlook to approximately $12 million. Ordering accounts and utilization both increased, though TearCare growth remains concentrated in a limited reimbursed footprint and broader payer access is not yet assured.
IG revenue grew 7% to $21 million, with active accounts at a record high; full-year IG guidance was raised to $80 million–$81 million. The company launched its next-generation OMNI Ultra in the U.S. and said expanded Aetna coverage adds about 25 million covered lives.
Cash used in the quarter fell to $2.4 million from $9.1 million a year earlier, while year-to-date cash use improved 48%; the company ended the quarter with $77.4 million in cash. Management said it remains focused on cash-flow breakeven and extended the debt interest-only period through August 2027.

Sight Sciences Stock Up 2.8%

Shares of SGHT stock traded up $0.26 during trading on Wednesday, hitting $9.68. 629,733 shares of the company were exchanged, compared to its average volume of 274,743. The business’s 50-day simple moving average is $8.63 and its 200 day simple moving average is $6.03. Sight Sciences has a twelve month low of $3.38 and a twelve month high of $10.06. The firm has a market capitalization of $533.27 million, a price-to-earnings ratio of -17.29 and a beta of 2.44. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.67 and a current ratio of 4.95.

Analyst Upgrades and Downgrades

SGHT has been the topic of a number of analyst reports. Wall Street Zen raised Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. HC Wainwright assumed coverage on Sight Sciences in a report on Thursday, October 15th. They set a “buy” rating and a $14.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. Citigroup boosted their price target on shares of Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, October 5th. Finally, UBS Group upped their price target on shares of Sight Sciences from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.25.

Read Our Latest Stock Analysis on SGHT

Insider Activity at Sight Sciences

In other Sight Sciences news, CTO David Badawi sold 7,797 shares of Sight Sciences stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $70,562.85. Following the completion of the sale, the chief technology officer owned 1,975,075 shares of the company’s stock, valued at $17,874,428.75. This trade represents a 0.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Brenton Taylor sold 2,988 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $26,443.80. Following the transaction, the executive vice president owned 261,990 shares in the company, valued at approximately $2,318,611.50. This represents a 1.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 47,646 shares of company stock worth $429,157 in the last 90 days. 30.40% of the stock is owned by corporate insiders.

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.